Data / Form D filings / Elucida Oncology, Inc.
Elucida Oncology, Inc.: Form D filings
Elucida Oncology, Inc., a biotechnology company in Monmouth Junction, NJ, filed 12 Form D notices with the SEC between 2017 and 2023. The latest, on August 3, 2023, reports $22.3 million sold of a $22.3 million offering to 107 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1 Deer Park Drive, Monmouth Junction, NJ, 08852
- Phone
- (646) 701-5391
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1704594
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 3, 2023 | Amendment | $22,284,600 | $22,284,600 | 107 | May 24, 2023 | sec.gov | |
| Jun 15, 2023 | New notice | $40,000,000 | $22,936,960 | $17,063,040 | 277 | May 24, 2023 | sec.gov |
| Mar 28, 2022 | New notice | $22,284,600 | $22,284,600 | 107 | Mar 11, 2022 | sec.gov | |
| Jan 12, 2021 | Amendment | $35,000,000 | $35,000,000 | 328 | Oct 28, 2020 | sec.gov | |
| Dec 29, 2020 | Amendment | $35,000,000 | $32,552,878 | $2,447,122 | 303 | Oct 28, 2020 | sec.gov |
| Dec 10, 2020 | Amendment | $35,000,000 | $27,236,639 | $7,763,361 | 149 | Oct 28, 2020 | sec.gov |
| Nov 10, 2020 | New notice | $35,000,000 | $17,693,118 | $17,306,882 | 149 | Oct 28, 2020 | sec.gov |
| Jun 4, 2020 | Amendment | $30,000,000 | $8,782,683 | $21,217,317 | 126 | May 13, 2020 | sec.gov |
| May 26, 2020 | New notice | $30,000,000 | $7,389,785 | $22,610,215 | 104 | May 13, 2020 | sec.gov |
| Feb 7, 2019 | Amendment | $30,000,000 | $28,759,605 | $1,240,395 | 175 | Aug 15, 2017 | sec.gov |
| Jan 3, 2019 | Amendment | $30,000,000 | $28,094,604 | $1,905,396 | 170 | Aug 15, 2017 | sec.gov |
| Aug 22, 2017 | New notice | $30,000,000 | $10,859,249 | $19,140,751 | 94 | Aug 15, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Tim Boris | Director | |
| Robert Ruffolo | Director | |
| David Zacardelli | Director | |
| Ulrich Wiesner | Director | |
| Gary Sender | Director | |
| Robert Essner | Executive Officer, Director | |
| Natalie MacDonald | Director | |
| Geno Germano | Executive Officer, Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Jul 31, 2023 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Elucida Oncology, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.